×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Mologen Files for Insolvency after Cancer Immunotherapy Phase III Flop
Labiotech.eu
Following the phase III failure of its immunotherapy drug for colorectal cancer in the summer, the German biotech Mologen has filed for...
56 months ago
Metastatic colorectal cancer: Mologen's Phase III trial fails to impress
Clinical Trials Arena
Colorectal cancer: This key finding has shaped the future direction for the drug as Mologen AG has confirmed that it will only pursue...
56 months ago
Melanoma Market to Witness Promising Growth, Predicts DelveInsight | Key Companies To Watch - IO Biotech, Merck ...
PR Newswire
PRNewswire/ -- DelveInsight's Melanoma Market Insights report includes a comprehensive understanding of current treatment practices...
10 months ago
MOLOGEN and ONCOLOGIE: Global assignment and co-development agreement relating to MOLOGEN's lead ...
Business Wire
MOLOGEN and ONCOLOGIE signed a global assignment and co-development agreement relating to MOLOGEN's lead compound lefitolimod.
68 months ago
Biotech of the week: Mologen, the Largest Publicly-listed Biotech of Berlin
Labiotech.eu
Come and check out our biotech of the week, Mologen, one of the leading biotech companies in the fields of cell-based therapies and DNA...
22 months ago
MOLOGEN AG Achieves Patient Enrollment Goal for Small Cell Lung Cancer IMPULSE Study with Developmental ...
Lung Disease News
Dr. Matthias Schroff, CEO of MOLOGEN AG, commented on the recent success news in a press release, “Lung cancer and especially small cell lung...
101 months ago
Cooperation to create a new Tuberculosis vaccine
Max-Planck-Gesellschaft
Max Planck Institute for Infection Biology and MOLOGEN initiate development of a new tuberculosis subunit vaccine in 2004.
234 months ago
Mologen Joins the Rapidly Growing List of EU Partners with the No#1 US Cancer Hospital
Labiotech.eu
Mologen (Germany) is now partnered with MD Anderson (US) for immunooncology trials for its colorectal and small-cell lung cancer therapies.
22 months ago
Glycotope appoints Dr Alfredo Zurlo as chief medical officer
PMLiVE
He joins the German clinical-stage immuno-oncology company from Mologen.
95 months ago
Colorectal Cancer Clinical Trials Pipeline Analysis Featuring 125+ Key Companies by DelveInsight
GlobeNewswire
Colorectal Cancer Pipeline constitutes 125+ key companies continuously working towards developing 150+ Colorectal Cancer treatment therapies...
18 months ago